Grace Therapeutics, Inc. (GRCE) Financial Ratios
16 years of historical data (2010–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
0.41
-1% vs avg
5yr avg: 0.41
30Y Low0.4·High0.4
ROE
↑
-14.9%
↓+51% vs avg
5yr avg: -30.4%
30Y Low-452%·High-5%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
GRCE Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Grace Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $35M | $28M | — | — | — | — | — | — | — | — | — |
| Enterprise Value | $13M | $5M | — | — | — | — | — | — | — | — | — |
| P/E Ratio → | -2.85 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.41 | 0.41 | — | — | — | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
GRCE EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
GRCE Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -14.9% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | 61.2% | — | — | — | -116.2% | 13.1% |
| Operating Margin | — | — | — | — | — | -8377.0% | — | — | — | -25526.3% | -4580.5% |
| Net Profit Margin | — | — | — | — | — | -10039.8% | — | — | — | -16777.6% | -611.7% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -14.9% | -14.9% | -19.8% | -48.2% | -12.0% | -57.3% | -212.3% | -452.1% | -125.9% | -20.0% | -4.7% |
| ROA | -13.2% | -13.2% | -16.9% | -40.8% | -10.3% | -46.1% | -85.4% | -144.0% | -85.8% | -18.4% | -3.7% |
| ROIC | -30.1% | -30.1% | -21.4% | -65.9% | -28.2% | -664.7% | — | — | -119.8% | -24.5% | -27.1% |
| ROCE | -23.5% | -23.5% | -15.4% | -51.9% | -16.7% | -43.0% | -126.3% | -192.1% | -93.0% | -29.2% | -29.0% |
GRCE Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $22M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 0.01 | 0.00 | 0.00 | 0.01 | 0.12 | 0.20 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.33 | -0.37 | -0.40 | -0.28 | -0.91 | -1.08 | -1.40 | -0.80 | -0.11 | -0.04 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | -62.19 | -83.41 | -123.76 | -53.82 | -4805.56 | -3053.95 |
Net cash position: cash ($22M) exceeds total debt ($0)
GRCE Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Grace Therapeutics, Inc.'s current ratio of 11.77x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 8.59x to 11.77x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.77 | 11.77 | 14.26 | 8.59 | 13.97 | 39.50 | 2.16 | 2.05 | 1.42 | 9.93 | 12.11 |
| Quick Ratio | 11.77 | 11.77 | 14.26 | 8.59 | 13.97 | 39.50 | 2.16 | 2.05 | 1.42 | 9.93 | 12.05 |
| Cash Ratio | 11.47 | 11.47 | 13.66 | 8.18 | 13.39 | 38.46 | 1.93 | 1.88 | 1.23 | 9.18 | 11.33 |
| Asset Turnover | — | — | — | — | — | 0.00 | — | — | — | 0.00 | 0.01 |
| Inventory Turnover | 2.69 | — | — | — | — | — | — | — | — | — | 2.69 |
| Days Sales Outstanding | — | — | — | — | — | 986.99 | — | — | — | 3867.67 | 1152.59 |
GRCE Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Grace Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — | — | — | — | — | — | — |
| Shares Outstanding | — | $12M | $7M | $7M | $6M | $2M | $2M | $1M | $364302 | $222082 | $221202 |
Peer Comparison
Compare GRCE with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 GRCEYou | $35M | -2.8 | — | — | — | — | -14.9% | -30.1% | — |
 RARE | $3B | -4.5 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 ACAD | $4B | 9.9 | 26.9 | 36.7 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 PTCT | $5B | 8.3 | 5.4 | 7.6 | 95.9% | 49.5% | — | — | 0.5 |
 ARVN | $652M | -8.0 | — | — | 98.0% | -43.8% | -16.2% | -22.4% | — |
 SRPT | $2B | -2.9 | — | — | 59.9% | -29.9% | -53.5% | -31.4% | — |
 BMRN | $10B | 30.1 | 15.9 | 14.4 | 77.1% | 16.6% | 5.9% | 7.4% | 1.0 |
 ALNY | $39B | 127.0 | 70.2 | 84.8 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 KRYS | $9B | 43.4 | 49.2 | 46.3 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 RCKT | $398M | -1.8 | — | — | — | — | -60.3% | -63.2% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 15 years · Updated daily
See GRCE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GRCE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare GRCE vs RARE
Side-by-side business, growth, and profitability comparison vs Ultragenyx Pharmaceutical Inc..
Start ComparisonGRCE — Frequently Asked Questions
Quick answers to the most common questions about buying GRCE stock.
What is Grace Therapeutics, Inc.'s P/E ratio?
Grace Therapeutics, Inc.'s current P/E ratio is -2.8x. This places it at the 50th percentile of its historical range.
What is Grace Therapeutics, Inc.'s ROE?
Grace Therapeutics, Inc.'s return on equity (ROE) is -14.9%. The historical average is -82.7%.
Is GRCE stock overvalued?
Based on historical data, Grace Therapeutics, Inc. is trading at a P/E of -2.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.